Acrux (ASX:ACR) and its commercial partner, TruPharma, have announced the launch of Dapsone 7.5% gel in the United States.
The prescription topical medication, designed for the treatment of acne vulgaris in children aged 9 and older, is set to differentiate itself from competitors by being packaged in a tube, as opposed to the standard pump bottle packaging.
The product will be available in 60-gram and 90-gram tubes, aligning with market standards.
Manufactured and packaged in the US, Dapsone 7.5% gel was approved by the Food and Drug Administration in both tube and bottle pump formats, with the tube selected for launch to enhance patient convenience and reduce environmental waste.
Acrux's CEO, Michael Kotsanis, expressed excitement about the launch, highlighting the ease of use and lower manufacturing impact of the tube packaging.
He added that the product's launch builds on the success of the Dapsone 5% gel released in 2024 and underscores Acrux's ability to advance its pipeline of topically applied prescription products.
According to IQVIA, the US market for branded and generic products in this category exceeded US$43 million and 171,000 packs in 2024.